Work

MA16.06 Real-world Survival with CRT+durvalumab for Unresectable, Stage III NSCLC in Canada: the RELEVANCE Study

Year: 2023

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2023.09.232

Authors: P. Wheatley-Price, V. Navani, A. Pabani, B. Routy, S. Snow, M.-H. Denault, Y. Kim, I. Syed, N. Devost, D. Hui, P. Arora, R. Velummailum, A. Springford, C. McKibbon, C. Ho

Institutions: University of Ottawa, Ottawa Hospital Research Institute, University of Calgary, Centre Hospitalier de l’Université de Montréal, Université de Montréal, Dalhousie University, Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, AstraZeneca (Canada), BC Cancer Agency

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4388092012

Cites:

Cited by: 5

Related to: 10